Erythropoietin as a neonatal neuroprotectant: basic and clinical studies

Published: June 9, 2009
Abstract Views: 187
Untitled (): 0
PDF: 663
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Neonatal brain injury Although there are many mechanisms by which the neonatal brain can sustain injury, perinatal asphyxia and preterm delivery are two common mechanisms. To date, effective treatment strategies to improve neurodevelopmental outcome are not yet available. Perinatal asphyxia occurs in 2-4 of every 1000 live-born term infants,1 and accounts for 23% of neonatal deaths world wide.2 In recently published hypothermia trials, between 55 and 62% of infants diagnosed with perinatal asphyxia treated with conventional therapy died or survived with significant neurodevelopmental disability.3,4

Dimensions

Altmetric

PlumX Metrics

Downloads

Citations

Supporting Agencies

How to Cite

Juul, S. (2009). Erythropoietin as a neonatal neuroprotectant: basic and clinical studies. Hematology Meeting Reports (formerly Haematologica Reports), 2(10). https://doi.org/10.4081/hmr.v2i10.471